Filing Details

Accession Number:
0001179110-15-011396
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-07-21 18:35:30
Reporting Period:
2015-07-20
Filing Date:
2015-07-21
Accepted Time:
2015-07-21 18:35:30
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1042074 Cymabay Therapeutics Inc. CBAY Pharmaceutical Preparations (2834) 943103561
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1588856 Kurt Emster Von C/O Cymabay Therapeutics, Inc.
7999 Gateway Blvd, Suite 130
Newark CA 94560
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-07-20 1,600,000 $2.81 1,600,000 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 17,326 Indirect By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005
Footnotes
  1. Consists of (i) 533,333 shares held by Abingworth Bioventures VI, LP ("ABV VI"), and (ii) 1,066,667 shares held by Abingworth Bioequities Master Fund Limited ("ABE," and collectively with ABV VI, the "Abingworth Funds").
  2. Abingworth LLP ("ALLP") provides advisory services to the Abingworth Funds. Kurt von Emster ("Emster") is a member of ALLP. Emster may be deemed the indirect beneficial owner of the shares through his indirect interest in the Abingworth Funds. Emster disclaims beneficial ownership of the shares except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that ALLP, the Abingworth Funds, Emster or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.